Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Opinion distributions and mean shadow ban strength versus time under shadow banning control policies for different objectives on a stochastic block model network. by Yen-Shao Chen (18264587)

Subjects:

Decreased presence of tubulin-GFP at axonal MTs in a pulse chase experiment suggests changes in MT replenishment with age. by Pilar Okenve-Ramos (18150546)

Phase 1 pre- and post-test Means (<i>M</i>), Standard Deviations (<i>SD</i>), between group effect sizes (<i>d</i>), and RMANOVA results (<i>F</i>-value, <i>p</i>-value) for interv... by Wendy C. Crone (2262169)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Simulation of the average densities/concentrations of the variables for model (2)–(21) with ENZ, Sip-T, anti-PD-1 (<i>A</i>₁) and anti-CTLA-4 (<i>A</i>₄). by Nourridine Siewe (5081834)

Simulation of the average densities/concentrations of the variables for model (2)–(21) with/without ENZ (ADT) at <i>γ</i>_<i>E</i> = 10⁻⁷ g/cm³⋅d.... by Nourridine Siewe (5081834)

Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i>_<i>k</i>; a–c and d–f decreasing porosity for outward and inward protection... by Akshay Anand (118579)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

The rate the bias decreases with sample duration is higher for cells with higher activity levels. by Liron Sheintuch (12078310)

Phase 2 pre- and post-test Means (<i>M</i>), Standard Deviations (<i>SD</i>), between group effect sizes (<i>d</i>), and RMANOVA results (<i>F</i>-value, <i>p</i>-value) for interv... by Wendy C. Crone (2262169)

Drug-induced decrease of cell anisotropy reduces pattern fidelity. by Camille Curantz (7456499)

“…<b>(B)</b> Quantifications of primordia spacing variability on phalloïdin-stained control flat skins (explant; triangles) and LatA-treated cultured explants (+LatA; squares) of Japanese quail embryos showed that LatA treatment caused a significant decrease in pattern fidelity at condensation stage (explants, <i>n</i> = 9; +LatA, <i>n</i> = 9; unpaired 2-tailed <i>t</i> test; <i>p</i> = 0.0233) and differentiation stage (explants, <i>n</i> = 8; +LatA, <i>n</i> = 9; <i>p</i> = 0.002). …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects: